biote (NASDAQ:BTMD) Issues Earnings Results

biote (NASDAQ:BTMD) issued its quarterly earnings data on Wednesday. The company reported $0.06 EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.03), FiscalAI reports. biote had a negative return on equity of 23.41% and a net margin of 14.07%.The company had revenue of $44.94 million for the quarter, compared to the consensus estimate of $46.02 million.

Here are the key takeaways from biote’s conference call:

• Q1 revenue fell 8.3% to $44.9M, with procedure revenue down 13.2% to $31.3M (including a ~$1.7M recall impact), while dietary supplement sales grew 19.1% to $11.0M driven by e‑commerce.
• The company voluntarily recalled certain hormone pellets in January, citing an estimated ~$1.7M revenue hit and ~$1.5M incremental costs; supply constraints reduced Asteria’s share of shipped pellets and disrupted sales efforts, with management saying normalization should occur by end of Q2.
• Biote expanded its commercial footprint to about 120 sales reps (25 new hires in Q1) and trained over 200 new practitioners (+16.5% YoY), which management expects to drive a return to growth as hires and trainees ramp (~6 months).
• Profitability and cash were pressured: adjusted EBITDA fell to $8.7M (19.4% margin), net income dropped to $2.7M from $15.8M year‑ago, and cash stood at $5.3M after repurchase liability repayment, signaling margin and liquidity strains.

biote Stock Performance

BTMD stock traded down $0.11 during mid-day trading on Thursday, hitting $2.10. 195,781 shares of the company were exchanged, compared to its average volume of 224,092. The firm has a market cap of $82.86 million, a P/E ratio of 2.79 and a beta of 1.71. The firm’s 50 day simple moving average is $1.81 and its 200 day simple moving average is $2.27. biote has a 1-year low of $1.27 and a 1-year high of $4.75.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Truist Financial cut their price target on shares of biote from $5.00 to $4.00 and set a “buy” rating on the stock in a research report on Thursday, April 16th. B. Riley Financial cut their price target on shares of biote from $3.00 to $2.00 and set a “neutral” rating on the stock in a research report on Thursday, March 12th. TD Cowen cut their price target on shares of biote from $3.00 to $2.50 and set a “buy” rating on the stock in a research report on Thursday, March 12th. Finally, National Bank Financial set a $2.50 price target on shares of biote in a research report on Thursday, March 12th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $2.75.

Institutional Trading of biote

Several hedge funds have recently bought and sold shares of the stock. Geode Capital Management LLC raised its holdings in biote by 1.3% during the 4th quarter. Geode Capital Management LLC now owns 620,256 shares of the company’s stock worth $1,613,000 after buying an additional 8,016 shares during the period. State Street Corp grew its stake in shares of biote by 17.3% during the 4th quarter. State Street Corp now owns 600,114 shares of the company’s stock worth $1,560,000 after acquiring an additional 88,402 shares in the last quarter. Renaissance Technologies LLC grew its stake in shares of biote by 5.7% during the 4th quarter. Renaissance Technologies LLC now owns 203,594 shares of the company’s stock worth $529,000 after acquiring an additional 10,900 shares in the last quarter. Rothschild Wealth LLC bought a new position in shares of biote during the 4th quarter worth approximately $380,000. Finally, Bridgeway Capital Management LLC grew its stake in shares of biote by 142.1% during the 2nd quarter. Bridgeway Capital Management LLC now owns 121,053 shares of the company’s stock worth $487,000 after acquiring an additional 71,053 shares in the last quarter. 21.68% of the stock is currently owned by institutional investors and hedge funds.

biote Company Profile

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.